Bortezomib use in a pediatric cardiac transplant center

Matthew D. Zinn, Thomas J. L'Ecuyer, Omar R. Fagoaga, Sanjeev Aggarwal

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Data are limited on the efficacy and safety of bortezomib for the treatment of AMR following OHT for pediatric acquired or CHD. Retrospective chart review identified patients who received bortezomib for acute (n = 3, within two wk of diagnosis) and chronic (n = 1, three months after diagnosis) AMR or as part of a desensitization regimen (n = 1). Bortezomib was associated with a 3-66% reduction in class I DSA and a 7-82% reduction in class II DSA. Two of the three acute AMR cases resolved by the first follow-up biopsy. Two patients with AMR resolution are currently well. One patient developed a second episode of AMR, which was unresponsive to bortezomib therapy and required retransplantation for progressive coronary allograft vasculopathy. One patient died shortly after the third cycle from multi-organ failure. The desensitization patient showed transient HLA reduction with two cycles, but died five months after transplant from sepsis. Complications included infection (3/5), peripheral neuropathy (2/5), AKI (2/5), and thrombocytopenia (3/5). Adverse events appear more common in critically ill patients. Bortezomib therapy resulted in variable DSA reduction and AMR resolution in AMR in OHT secondary to pediatric acquired or CHD.

Original languageEnglish
Pages (from-to)469-476
Number of pages8
JournalPediatric Transplantation
Issue number5
StatePublished - Aug 2014


  • antibody-mediated rejection
  • bortezomib
  • congenital heart disease
  • orthotopic heart transplantation


Dive into the research topics of 'Bortezomib use in a pediatric cardiac transplant center'. Together they form a unique fingerprint.

Cite this